Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-EBV autologous TCR-T cell injection
- Development stage
- Phase 1
- Lead developer
- Shanghai General Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an autologous T-cell receptor-engineered T-cell (TCR-T) therapy being developed by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, under the leadership of Dr. Xianmin Song. The therapy involves the genetic modification of a patient's own T cells to express T-cell receptors (TCRs) specifically designed to recognize Epstein-Barr virus (EBV) antigens presented by the HLA-A11:01 molecule. It is intended for the treatment of relapsed or refractory EBV-positive lymphomas. By targeting EBV-infected malignant cells, the therapy aims to provide a precise, immune-mediated elimination of the tumor. It is currently being evaluated in a Phase 1 dose-escalation clinical trial (NCT07162012) to assess safety, tolerability, and preliminary efficacy in patients aged 18-70.
- Other names
- Epstein-Barr virus T-cell receptor-engineered T-cellsanti-EBV TCR-T cellsanti-EBV autologous TCR-T cell
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on anti-EBV autologous TCR-T cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-EBV autologous TCR-T cell injection.